Trials / Completed
CompletedNCT02383368
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients With Advanced Refractory Solid Tumors and Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132. The study will also determine the pharmacokinetics (PK) of ASP4132 and evaluate the preliminary antitumor activity.
Detailed description
The study consists of two parts and these will be conducted sequentially: Part 1 (dose escalation) and Part 2 (dose expansion). Subjects will participate in Part 1 or Part 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP4132 | oral |
Timeline
- Start date
- 2015-03-23
- Primary completion
- 2018-04-27
- Completion
- 2018-04-27
- First posted
- 2015-03-09
- Last updated
- 2024-10-31
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02383368. Inclusion in this directory is not an endorsement.